Skip to main content

Advertisement

SpringerLink
Log in

Quality of psoriasis care in Germany: results of the national health care study “PsoHealth3”

  • Original Paper
  • Published:
Archives of Dermatological Research Aims and scope Submit manuscript

Abstract

Two national surveys conducted in 2005 and 2007 indicated deficits in psoriasis care and induced the composition of the ‘‘National Goals for Health Care in Psoriasis 2010–2015’’. The aim of this work was to (1) evaluate the quality of care for patients with psoriasis in Germany, (2) compare this with prior psoriasis studies PsoHealth1 (2005) and PsoHealth2 (2007), and (3) review the implementation of national treatment goals. By means of a cross sectional study the following indicators of health care quality were collected: psoriasis severity (Psoriasis Area Severity Index (PASI) and proportion of PASI >20), quality of life (Dermatology Life Quality Index (DLQI) were corporated: proportion of DLQI >10), previous systemic treatment, inpatient treatment, and days absent from work due to psoriasis. Between January 2013 and March 2014, 1265 patients from 82 dermatological centres were included (mean age of 52 years). 9.2 % had a PASI >20 (2007: 11.6 %; 2005: 17.8 %). 21.3 % reported strong quality of life restrictions (DLQI >10) (2007: 28.2 %; 2005: 34.0 %). 59.5 % had received a systemic treatment at least once within the last 5 years (2007: 47.3 %; 2005: 32.9 %). 20.1 % were treated inpatient within the last 5 years (2007: 20.1 %; 2005: 26.9 %). The current data indicate a better health care situation for psoriasis in Germany. The implementation of the S3-Guideline and the ‘‘National Goals for Health Care in Psoriasis 2010–2015’’ could have been contributing factors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Augustin M (2008) PsoNet—more health care quality through regional psoriasis networks. J Dtsch Dermatol Ges 6(4):263–264

    Article  PubMed  Google Scholar 

  2. Augustin M, Alvaro-Gracia JM, Bagot M et al (2012) A framework for improving the quality of care for people with psoriasis. J Eur Acad Dermatol Venereol 26(Suppl 4):1–16

    Article  PubMed  Google Scholar 

  3. Augustin M, Chapnik J, Gupta S et al (2011) Psoriasis causes high costs, reduces productivity at work and quality of life. Akt Dermatol 37(10):353–359

    Article  Google Scholar 

  4. Augustin M, Glaeske G, Radtke MA et al (2010) Epidemiology and comorbidity of psoriasis in children. Br J Dermatol 162(3):633–636

    Article  CAS  PubMed  Google Scholar 

  5. Augustin M, Glaeske G, Schäfer I et al (2012) Processes of Psoriasis Health Care in Germany—long-term analysis of data from the statutory health insurances. J Dtsch Dermatol Ges 10(9):648–655

    PubMed  Google Scholar 

  6. Augustin M, Herberger K, Hintzen S et al (2011) Prevalence of skin lesions and need for treatment in a cohort of 90,880 workers. Br J Dermatol 165(4):865–873

    Article  CAS  PubMed  Google Scholar 

  7. Augustin M, Krüger K, Radtke MA et al (2008) Disease severity, quality of life and health care in plaque-type psoriasis: a multicenter cross-sectional study in Germany. Dermatology 216(4):366–372

    Article  CAS  PubMed  Google Scholar 

  8. Augustin M, Radtke MA, Zschocke I et al (2009) The patient benefit index: a novel approach in patient-defined outcomes measurement for skin diseases. Arch Dermatol Res 301(8):561–571

    Article  PubMed  Google Scholar 

  9. Augustin M, Reich K, Blome C et al (2010) Nail psoriasis in Germany: epidemiology and burden of disease. Br J Dermatol 163(3):580–585

    Article  CAS  PubMed  Google Scholar 

  10. Augustin M, Reich K, Glaeske G et al (2013) Drug supply for children with psoriasis in Germany. J Dtsch Dermatol Ges 11(8):751–755

    PubMed  Google Scholar 

  11. Augustin M, Reich K, Reich C et al (2008) Quality of psoriasis care in Germany—results of the national study PsoHealth 2007. J Dtsch Dermatol Ges 6(8):640–645

    Article  PubMed  Google Scholar 

  12. Augustin M, Schäfer I, Reich K et al (2011) Systemic treatment with corticosteroids in psoriasis-health care provision far beyond the S3-guidelines. J Dtsch Dermatol Ges 9(10):833–838

    PubMed  Google Scholar 

  13. Augustin M, Zschocke I, Seidenglanz K et al (2000) Validation and clinical results of the FLQA-d, a quality of life questionnaire for patients with chronic skin diseases. Dermatol Psychosom 1(1):12–17

    Article  Google Scholar 

  14. Blome C, Simianer S, Purwins S et al (2010) Time needed for treatment is the major predictor of quality of life in psoriasis. Dermatology 221(2):154–159

    Article  PubMed  Google Scholar 

  15. Deutsche Dermatologische Gesellschaft (DDG), Berufsverband der Deutschen Dermatologen (BVDD) (2015) Regionale Psoriasisnetze in Deutschland. http://www.psonet.de. Accessed 6 Jan 2015

  16. Deutsche Dermatologische Gesellschaft (DDG), Berufsverband der Deutschen Dermatologen (BVDD), Competenzzentrum Versorgungsforschung in der Dermatologie (CVderm) (2014) Psoriasis Nationale Versorgungsziele. http://www.versorgungsziele.de/. Accessed 19 Dec 2014

  17. Dubertret L, Mrowietz U, Ranki A et al (2006) European patient perspectives on the impact of psoriasis: the EUROPSO patient membership survey. Br J Dermatol 155(4):729–736

    Article  CAS  PubMed  Google Scholar 

  18. Feldman SR, Krueger GG (2005) Psoriasis assessment tools in clinical trials. Ann Rheum Dis 64(Suppl 2):ii65–ii68

    PubMed  PubMed Central  Google Scholar 

  19. Feuerhahn J, Blome C, Radtke M et al (2012) Validation of the patient benefit index for the assessment of patient-relevant benefit in the treatment of psoriasis. Arch Dermatol Res 304(6):433–441

    Article  PubMed  Google Scholar 

  20. Finlay AY, Khan GK (1994) Dermatology Life Quality Index (DLQI)—a simple practical measure for routine clinical use. Clin Exp Dermatol 19(3):210–216

    Article  CAS  PubMed  Google Scholar 

  21. Kimball AB, Gieler U, Linder D et al (2010) Psoriasis: is the impairment to a patient’s life cumulative? J Eur Acad Dermatol Venereol 24(9):989–1004

    CAS  PubMed  Google Scholar 

  22. Krueger G, Koo J, Lebwohl M et al (2001) The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 137(3):280–284

    CAS  PubMed  Google Scholar 

  23. Nast A, Kopp IB, Augustin M et al (2006) S3-guidelines for the treatment of psoriasis vulgaris. J Dtsch Dermatol Ges 4(Suppl2):S1–126

    Article  PubMed  Google Scholar 

  24. Radtke MA, Reich K, Blome C et al (2009) Evaluation of quality of care and guideline-compliant treatment in psoriasis. Development of a new system of quality indicators. Dermatology 219(1):54–58

    Article  CAS  PubMed  Google Scholar 

  25. Radtke MA, Reich K, Blome C et al (2009) Prevalence and clinical features of psoriatic arthritis and joint complaints in 2009 patients with psoriasis: results of a German national survey. J Eur Acad Dermatol Venereol 23(6):683–691

    Article  CAS  PubMed  Google Scholar 

  26. Reich K, Krüger K, Mössner R et al (2009) Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis. Br J Dermatol 160(5):1040–1047

    Article  CAS  PubMed  Google Scholar 

  27. Schmid-Ott G, Künsebeck H, Jäger B et al (2005) Significance of the stigmatization experience of psoriasis patients: a 1-year follow-up of the illness and its psychosocial consequences in men and women. Acta Derm Venereol 85(1):27–32

    Article  PubMed  Google Scholar 

  28. Schöffski O, Augustin M, Prinz J et al (2007) Costs and quality of life in patients with moderate-to-severe plaque-type psoriasis in Germany: a multi-center study. J Dtsch Dermatol Ges 5(3):209–218

    Article  PubMed  Google Scholar 

  29. Sohn S, Schoeffski O, Prinz J et al (2006) Cost of moderate to severe plaque psoriasis in Germany: a multicenter cost-of-illness study. Dermatology 212(2):137–144

    Article  CAS  PubMed  Google Scholar 

  30. Taylor WJ (2012) Impact of psoriatic arthritis on the patient: through the lens of the WHO International Classification of Functioning, Health, and Disability. Curr Rheumatol Rep 14(4):369–374

    Article  PubMed  Google Scholar 

  31. Zachariae H, Zachariae R, Blomqvist K et al (2002) Quality of life and prevalence of arthritis reported by 5,795 Members of the Nordic Psoriasis Associations. Data from the Nordic Quality of Life Study. Acta Derm Venereol 82(2):108–113

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

The authors wish to thank all participating centres, the German Psoriasis Network (PsoNet), and the Professional Association of German Dermatologists (BVDD) and the German Society of Dermatology (DDG) for their cooperation in this study. We also thank Biogen for providing financial support to this study.

Funding

Biogen provided financial support for this study.

Author information

Authors and Affiliations

  1. Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany

    Anna Langenbruch, Marc Alexander Radtke, Arnd Jacobi, Sandra Purwins, Kristina Haack & Matthias Augustin

  2. Dermatologikum Hamburg, Hamburg, Germany

    Kristian Reich

  3. Professional Association of German Dermatologists (BVDD), Mönchengladbach, Germany

    Klaus Stroemer

  4. Clinic for Dermatology, Venerology and Allergology, University Medical Hospital, Kiel, Germany

    Ulrich Mrowietz

Authors
  1. Anna Langenbruch
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marc Alexander Radtke
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Arnd Jacobi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sandra Purwins
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kristina Haack
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Kristian Reich
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Klaus Stroemer
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Ulrich Mrowietz
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Matthias Augustin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Anna Langenbruch.

Ethics declarations

Conflicts of interest

Anna Langenbruch, Sandra Purwins, and Kristina Haack declare no conflicts of interest. Marc Alexander Radtke was or is involved as a researcher in clinical and healthcare research studies, or had lecturing activities for the companies, such as Abbvie, Pfizer, Biogen, Janssen, MSD, Celgene, Novartis, Mundipharma, Leo-Pharma, Medac, and Lilly. Arnd Jacobi was or is involved as a researcher in clinical and healthcare research studies, or had lecturing activities for the companies, such as Abbvie, Pfizer, Biogen, Janssen, MSD, Celgene, Novartis, UCB, Leo-Pharma, Medac, and Lilly. Klaus Strömer has received fees for lecturing from a number of companies which produce topical or systemic treatments: Leo Pharma, Novartis, Janssen, Abbvie, Biogen, and Wyeth. He has received advisory fees from a number of companies which produce topical or systemic treatments: Leo Pharma, Novartis, Janssen, Abbvie, Biogen, and Wyeth. Ulrich Mrowietz has been working as an advisor and/or presenter and/or recipient of research support and/or participant at clinical studies for the following companies: Abbott/AbbVie, Almirall-Hermal, Amgen, BASF, Biogen, Celgene, Centocor, Eli Lilly, Forward Pharma, Galderma, Janssen-Cilag, Leo Pharma, medac, MSD, Miltenyi Biotech, Novartis, Pfizer, Teva, VBL, and Xenoport. Kristian Reich has performed paid advising, held lectures, and took part in clinical studies for the companies, such as Abbott, Almirall, Amgen, Biogen, Celgene, Centocor, Eli Lilly, Janssen-Cilag, Leo, Medac, MSD (formerly Essex, Schering-Plough), Novartis, Pfizer (formerly Wyeth), and Xenoport. Matthias Augustin has performed paid advising, held lectures, and took part in clinical studies for the companies, such as Abbott, Almirall, Amgen, Biogen, Celgene, Centocor, Janssen-Cilag, Leo, Lilly, Medac, MSD (formerly Essex, Schering-Plough), Novartis, Pfizer (formerly Wyeth), UCB, and Xenoport.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Langenbruch, A., Radtke, M.A., Jacobi, A. et al. Quality of psoriasis care in Germany: results of the national health care study “PsoHealth3”. Arch Dermatol Res 308, 401–408 (2016). https://doi.org/10.1007/s00403-016-1651-x

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00403-016-1651-x

Keywords

Search

Navigation